1. Market Research
  2. > Healthcare
  3. > Blood Supply, Tissue Banking and Transplantation Market Trends
  4. > EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023

EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023

Summary

Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of aGVHD in the 6MM, from 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed incident cases in 2023, at an Annual Growth Rate (AGR) of 4.35% during the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of cGVHD in the 6MM, from 7,359 diagnosed incident cases in 2013 to 10,485 diagnosed incident cases in 2023, at an AGR of 4.25% during the forecast period.

To forecast the diagnosed incident cases of aGVHD and cGVHD in the 6MM, GlobalData epidemiologists selected nationally-representative studies that provided the diagnosed incidence of aGVHD and cGVHD using the uniform validated diagnostic criteria and classification defined by the Center International Blood and Marrow Transplant Research standard grading system for aGVHD, and the standard criteria for cGVHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGVHD and cGVHD cases. Another strength of this analysis is that the same methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed incident GVHD cases.

Scope

- The Graft-Versus-Host Disease (GVHD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for the diagnosed incidence of hematopoietic stem cell transplantations (HSCTs) (including first, multiple, and re-transplants), segmented by transplant type (autologous and allogeneic), and the diagnosed incident cases of GVHD in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). GlobalData epidemiologists also forecast the four-year diagnosed prevalent cases of acute GVHD (aGVHD) and the five-year diagnosed prevalent cases of chronic GVHD (cGVHD) in the 6MM.
- The GVHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global GVHD market.
- Quantify patient populations in the global GVHD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the groups that present the best opportunities for GVHD therapeutics in each of the markets covered.
- Identify the number of incident and prevalent aGVHD and cGVHD cases.

Table Of Contents

EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 13
3.4 Forecast Methodology 14
3.4.1 Sources Used 16
3.4.2 Sources Not Used 24
3.4.3 Forecast Assumptions and Methods 24
3.5 Epidemiological Forecast for GVHD (2013-2023) 30
3.5.1 Diagnosed Incident Cases of HSCTs 30
3.5.2 Diagnosed Incident Cases of Autologous HSCTs 32
3.5.3 Diagnosed Incident Cases of Allogeneic HSCTs 33
3.5.4 Diagnosed Incident Cases of aGVHD 35
3.5.5 Four-Year Diagnosed Prevalent Cases of aGVHD 37
3.5.6 Diagnosed Incident Cases of cGVHD 39
3.5.7 Five-Year Diagnosed Prevalent Cases of cGVHD 40
3.6 Discussion 42
3.6.1 Epidemiological Forecast Insight 42
3.6.2 Limitations of the Analysis 43
3.6.3 Strengths of the Analysis 44
4 Appendix 45
4.1 Bibliography 45
4.2 About the Authors 50
4.2.1 Epidemiologists 50
4.2.2 Reviewers 50
4.2.3 Intrim Director of Epidemiology 52
4.2.4 Global Director of Epidemiology (Through May 2014) 52
4.2.5 Global Head of Healthcare 53
4.3 About GlobalData 54
4.4 About EpiCast 54
4.5 Disclaimer 55

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for GVHD 12
Table 2: 6MM, Sources of HSCT, aGVHD, and cGVHD Data Used for the Forecast 16
Table 3: 6MM, Sources Not Used in the Epidemiological Analysis of GVHD 24
Table 4: 6MM, Diagnosed Incident Cases of HSCTs, Both Sexes, All Ages, N, 2013-2023 31
Table 5: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023 32
Table 6: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023 34
Table 7: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023 36
Table 8: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 38
Table 9: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 39
Table 10: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 41

1.2 List of Figures

Figure 1: Flow Chart of Derivation of aGVHD and cGVHD Patient Population in the 6MM 14
Figure 2: 6MM, Diagnosed Incident Cases of HSCTs , Both Sexes, All Ages, N, 2013-2023 31
Figure 3: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023 33
Figure 4: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023 35
Figure 5: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023 37
Figure 6: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, 2013-2023 38
Figure 7: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 40
Figure 8: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 41

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tissue Banking Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2024

Tissue Banking Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Global Tissue Banking Market: Overview Tissue Banking devices are used to store tissues in controlled environment for quality, safety and effective use in different disease treatment. The report on global ...

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises ...

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global plasma fractionation market is estimated to grow at a CAGR of 6.7% from 2016 to 2021, to reach USD 26.07 billion by 2021 from USD 18.84 billion in 2016. Growth in this market is mainly attributed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.